China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

Chinese drugmaker InnoCare Pharma SSE:688428 said on Thursday it entered into a research collaboration and license agreement with Eli Lilly NYSE:LLY that could be worth up to about $3.35 billion.